Theravance Biopharma (TBPH) AI Stock Analysis

• Market Cap: $892.34M
• Dividend Yield: N/A
• Average Volume (3M): 526.98K
• Price to Earnings (P/E): 31.4
• Beta (1Y): 0.95
• Revenue Growth: 27.12%
• EPS Growth: N/A
• Country: US
• Employees: 97
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.07
• Shares Outstanding: 50,672,432
• 10 Day Avg. Volume: 384,770
• 30 Day Avg. Volume: 526,982
• PEG Ratio: -0.54
• Price to Book (P/B): 2.62
• Price to Sales (P/S): 7.14
• P/FCF Ratio: -38.73
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 5.89
• Enterprise Value/Gross Profit: 9.40
• Enterprise Value/Ebitda: -18.29
• 1Y Price Target: $28.40
• Price Target Upside: 56.30% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 1.88
• Revenue Forecast (FY): $122.06M

• Rating: 61 Neutral
• Price Target: $19.00 ▲(4.57% Upside)

Theravance Biopharma's overall stock score reflects a combination of strong earnings call results and technical indicators, alongside moderate financial performance and valuation. The company's robust cash position and strategic milestones contribute positively, while operational challenges and historical equity fluctuations present risks. The stock's bullish technical trend and growth-oriented valuation further support the score.

Positive Factors

Strong Cash Position

A robust cash position with no debt enhances financial flexibility, enabling strategic investments and resilience against market fluctuations.

Revenue Growth from YUPELRI

Sustained revenue growth from YUPELRI indicates strong market demand and pricing power, supporting long-term revenue stability.

Progress in Clinical Trials

Advancement in clinical trials for ampreloxetine could lead to new product approvals, expanding the company's market presence and revenue base.

Negative Factors

Operational Challenges

Operational challenges in trial execution can delay product development and market entry, affecting long-term growth prospects.

Negative EBIT and EBITDA Margins

Persistent negative margins suggest inefficiencies in operations, potentially impacting profitability and cash flow sustainability.

Historical Equity Fluctuations

Volatility in equity levels can indicate financial instability, affecting investor confidence and the company's ability to raise capital.

Theravance Biopharma Business Overview & Revenue Model

Company Description

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

How the Company Makes Money

Theravance Biopharma generates revenue primarily through the commercialization of its pharmaceutical products. Key revenue streams include product sales from its approved therapies, such as the inhaled dual bronchodilator, YUPELRI (revefenacin), which is used for the treatment of chronic obstructive pulmonary disease (COPD). The company may also earn revenue through strategic partnerships and collaborations with other biopharmaceutical firms, where they may receive milestone payments, royalties on sales, and research funding. Additionally, Theravance could potentially benefit from licensing agreements that allow other companies to develop and market its products, further diversifying its revenue sources.

Theravance Biopharma Financial Statement Overview

Summary

Theravance Biopharma shows signs of financial recovery with improved profitability and cash flow management. The income statement reveals a positive net profit margin and strong gross profit margin, but negative EBIT and EBITDA margins indicate operational challenges. The balance sheet is stable with low leverage, although historical equity fluctuations pose risks. Cash flow management is strong, with efficient cash conversion.

Income Statement

Theravance Biopharma's income statement shows a mixed performance. The company has achieved a positive net profit margin of 16.88% in the TTM period, a significant improvement from previous losses. However, the EBIT and EBITDA margins remain negative, indicating ongoing operational challenges. Revenue growth is modest at 4.04%, suggesting a slow recovery. The gross profit margin is strong at 100% in the TTM, but historical volatility in profitability is a concern.

Balance Sheet

The balance sheet reflects moderate financial stability. The debt-to-equity ratio is low at 0.21, indicating manageable leverage. Return on equity has improved to 8.18% in the TTM, showing better utilization of equity. However, the equity ratio is not explicitly provided, and historical fluctuations in equity levels suggest potential risks.

Cash Flow

Theravance Biopharma's cash flow statement indicates strong cash flow management in the TTM period. The operating cash flow to net income ratio is robust at 4.48, and free cash flow to net income is nearly 1, showing efficient cash conversion. Despite a slight decline in free cash flow growth, the company has improved its cash flow position significantly compared to previous years.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	80.33M	64.38M	57.42M	51.35M	55.31M	71.86M
Gross Profit	50.27M	64.38M	16.80M	-12.05M	-138.35M	71.86M
EBITDA	-25.84M	-38.45M	-51.65M	-76.08M	-232.83M	-287.82M
Net Income	29.34M	-56.42M	-55.19M	872.13M	-199.43M	-278.02M
Balance Sheet
Total Assets	415.46M	354.16M	382.00M	607.40M	374.82M	469.06M
Cash, Cash Equivalents and Short-Term Investments	329.68M	88.35M	102.43M	327.48M	173.47M	292.94M
Total Debt	44.59M	49.82M	49.16M	52.16M	669.52M	676.26M
Total Liabilities	182.78M	178.62M	169.00M	165.60M	713.39M	772.81M
Stockholders Equity	232.68M	175.54M	213.00M	441.80M	-338.57M	-303.75M
Cash Flow
Free Cash Flow	243.48M	-11.87M	-29.48M	-187.56M	-211.26M	-257.02M
Operating Cash Flow	243.70M	-11.54M	-27.00M	-186.99M	-207.86M	-250.40M
Investing Cash Flow	-90.19M	12.28M	-32.70M	1.15B	124.49M	10.72M
Financing Cash Flow	-2.12M	-2.50M	-198.93M	-758.81M	91.86M	263.08M

Theravance Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TBPH, the sentiment is Positive. The current price of 18.17 is below the 20-day moving average (MA) of 18.47, above the 50-day MA of 16.23, and above the 200-day MA of 12.29, indicating a neutral trend. The MACD of 0.48 indicates Positive momentum. The RSI at 54.50 is Neutral, neither overbought nor oversold. The STOCH value of 21.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TBPH.

Theravance Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$364.54M	―	-43.11%	―	―	-5.71%
TBPH	61 Neutral	$892.34M	31.43	14.03%	―	27.12%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DAWN	50 Neutral	$873.77M	―	-30.16%	―	31.11%	-46.75%
MRVI	49 Neutral	$953.79M	―	-41.06%	―	-30.56%	48.79%
NBTX	48 Neutral	$1.09B	―	―	―	―	―
TERN	45 Neutral	$4.02B	―	-29.12%	―	―	12.45%

Theravance Biopharma Corporate Events

Theravance Biopharma Hosts Key Opinion Leader Event

On December 8, 2025, Theravance Biopharma held a virtual key opinion leader event for investors, focusing on its investigational product Ampreloxetine, which is being studied for treating symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. The company also announced its 2026 Annual General Meeting of Shareholders scheduled for June 12, 2026, in Dublin, Ireland. The event highlighted the company’s strong financial position, with a cash balance of $332.7 million as of September 30, 2025, and its strategic focus on advancing in-house developed assets through approval and commercialization. The upcoming Phase 3 data for Ampreloxetine is expected to be a significant catalyst for the company, aiming to address an underserved patient population in the U.S.